Bank of New York Mellon Corp Increases Holdings in Elevance Health, Inc. $ELV

Bank of New York Mellon Corp lifted its holdings in Elevance Health, Inc. (NYSE:ELV) by 3.3% in the third quarter, Holdings Channel reports. The fund owned 1,343,639 shares of the company’s stock after purchasing an additional 42,821 shares during the quarter. Bank of New York Mellon Corp’s holdings in Elevance Health were worth $434,157,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Janney Montgomery Scott LLC increased its position in shares of Elevance Health by 0.6% during the 2nd quarter. Janney Montgomery Scott LLC now owns 48,049 shares of the company’s stock valued at $18,689,000 after purchasing an additional 272 shares during the last quarter. HB Wealth Management LLC boosted its stake in Elevance Health by 8.1% during the second quarter. HB Wealth Management LLC now owns 21,747 shares of the company’s stock worth $8,459,000 after buying an additional 1,629 shares during the period. Raleigh Capital Management Inc. boosted its stake in Elevance Health by 24.7% during the second quarter. Raleigh Capital Management Inc. now owns 278 shares of the company’s stock worth $108,000 after buying an additional 55 shares during the period. Trivium Point Advisory LLC increased its position in Elevance Health by 12.9% during the second quarter. Trivium Point Advisory LLC now owns 629 shares of the company’s stock valued at $245,000 after acquiring an additional 72 shares during the last quarter. Finally, PBMares Wealth Management LLC raised its stake in shares of Elevance Health by 12.6% in the second quarter. PBMares Wealth Management LLC now owns 858 shares of the company’s stock valued at $334,000 after acquiring an additional 96 shares during the period. 89.24% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the stock. Wells Fargo & Company lifted their price target on shares of Elevance Health from $403.00 to $424.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 7th. Barclays boosted their target price on Elevance Health from $385.00 to $404.00 and gave the company an “overweight” rating in a research report on Monday, January 5th. Robert W. Baird increased their price target on Elevance Health from $297.00 to $340.00 and gave the stock a “neutral” rating in a report on Thursday, December 11th. Guggenheim upped their price objective on Elevance Health from $398.00 to $414.00 and gave the company a “buy” rating in a research report on Thursday, January 22nd. Finally, Weiss Ratings upgraded Elevance Health from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, January 12th. Twelve research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat, Elevance Health currently has an average rating of “Moderate Buy” and a consensus price target of $399.63.

Elevance Health Trading Up 5.9%

ELV opened at $342.01 on Thursday. The company has a quick ratio of 1.56, a current ratio of 1.56 and a debt-to-equity ratio of 0.71. The stock’s fifty day moving average is $350.56 and its two-hundred day moving average is $328.87. The company has a market capitalization of $76.01 billion, a P/E ratio of 13.98, a PEG ratio of 1.66 and a beta of 0.51. Elevance Health, Inc. has a 52 week low of $273.71 and a 52 week high of $458.75.

Elevance Health (NYSE:ELV) last posted its quarterly earnings results on Wednesday, January 28th. The company reported $3.33 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.10 by $0.23. The business had revenue of $49.31 billion for the quarter, compared to the consensus estimate of $49.52 billion. Elevance Health had a return on equity of 16.17% and a net margin of 2.84%.The business’s revenue was up 9.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $3.84 EPS. Elevance Health has set its FY 2026 guidance at 25.500- EPS. Analysts forecast that Elevance Health, Inc. will post 33.96 earnings per share for the current year.

Elevance Health Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, March 25th. Stockholders of record on Tuesday, March 10th will be issued a $1.72 dividend. The ex-dividend date is Tuesday, March 10th. This represents a $6.88 annualized dividend and a dividend yield of 2.0%. This is an increase from Elevance Health’s previous quarterly dividend of $1.71. Elevance Health’s dividend payout ratio (DPR) is presently 27.96%.

Elevance Health News Roundup

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Q4 EPS beat consensus ($3.33 vs. $3.10) and management cited rising premiums plus a surge in Carelon revenues — a key reason investors see continued earnings resilience. Elevance Health Q4 Earnings Beat
• Positive Sentiment: Board raised the quarterly dividend to $1.72 (annualized yield ~2.0%), a modest increase from $1.71 — supportive for income-focused shareholders and signals confidence in cash flow.
• Neutral Sentiment: Revenue grew ~9.6% YoY to $49.31B but came in slightly below consensus; net margin and ROE remain modest, so growth is present but profit dynamics are mixed. Press Release / Slide Deck
• Negative Sentiment: FY‑2026 EPS guidance was lowered to about 25.50, below the Street (~26.89); management warned medical costs will remain elevated, which is a direct near‑term headwind to margins and valuation. Elevance forecasts 2026 profit below estimates
• Negative Sentiment: Market commentary highlights Medicare Advantage and reimbursement/membership pressures as reasons for selloff and heightened volatility in ELV shares following the earnings release. Barron’s: Earnings adding to Medicare pain

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.